Alterations of Antioxidant Enzymes and Biomarkers of Nitro-oxidative Stress in Tissues of Bladder Cancer

Oxidative Medicine and Cellular Longevity

Volumn 2019, Issue , 2019, Pages

  Obaidul Islam, M ^a   Bacchetti, Tiziana T ^a   Ferretti, Gianna ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANTS; DISEASES; ENZYMES; HISTOLOGY; LIPIDS; NITRIC OXIDE; NUCLEIC ACIDS; OXIDANTS; OXIDATION; OXYGEN; TISSUE;

ANTIOXIDANT DEFENSE; CELL SURVIVAL AND PROLIFERATIONS; LIPID PEROXIDATION; LOW CONCENTRATIONS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SUPER OXIDE DISMUTASE; URINARY BLADDER CANCER;

OXIDATIVE STRESS;

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; CATALASE; GLUTATHIONE; NITRIC OXIDE; NUCLEIC ACID; OXIDIZING AGENT; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; BIOLOGICAL MARKER;

BLADDER CANCER; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; ANIMAL; BLADDER TUMOR; METABOLISM; PHYSIOLOGY;

ANTIOXIDANTS; DISEASES; ENZYMES; HISTOLOGY; LIPIDS; NUCLEIC ACIDS;

ANIMALS; ANTIOXIDANTS; BIOMARKERS; HUMANS; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; URINARY BLADDER NEOPLASMS;

EID: 85068197435     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2019/2730896     Document Type: Review

References (60)

1. D. M. Parkin, “The global burden of urinary bladder cancer,” Scandinavian Journal of Urology and Nephrology, vol. 42, Supplement 218, pp. 12-20, 2008.
2. S. F. Shariat, J. A. Karam, Y. Lotan, and P. I. Karakiewizc, “Critical evaluation of urinary markers for bladder cancer detection and monitoring,” Reviews in Urology, vol. 10, no. 2, pp. 120-135, 2008.
3. J. Bellmunt, A. Orsola, J. J. Leow et al., “Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 25, Supplement_3, pp. iii40-iii48, 2014.
4. J. Ferris, O. Berbel, J. Alonso-Lopez, J. Garcia, and J. A. Ortega, “Environmental non-occupational risk factors associated with bladder cancer,” Actas Urológicas Españolas (English Edition), vol. 37, no. 9, pp. 579-586, 2013.
5. D. Volanis, T. Kadiyska, A. Galanis, D. Delakas, S. Logotheti, and V. Zoumpourlis, “Environmental factors and genetic susceptibility promote urinary bladder cancer,” Toxicology Letters, vol. 193, no. 2, pp. 131-137, 2010.
6. K. Jomova, Z. Jenisova, M. Feszterova et al., “Arsenic: toxicity, oxidative stress and human disease,” Journal of Applied Toxicology, vol. 31, no. 2, pp. 95-107, 2011.
7. B. Isik, A. Ceylan, and R. Isik, “Oxidative stress in smokers and non-smokers,” Inhalation Toxicology, vol. 19, no. 9, pp. 767-769, 2007.
8. S. Petruzzelli, R. Puntoni, P. Mimotti et al., “Plasma 3-nitrotyrosine in cigarette smokers,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 6, pp. 1902-1907, 1997.
9. F. Henkler, J. Brinkmann, and A. Luch, “The role of oxidative stress in carcinogenesis induced by metals and xenobiotics,” Cancers, vol. 2, no. 2, pp. 376-396, 2010.
10. T. E. Eling, D. C. Thompson, G. L. Foureman, J. F. Curtis, and M. F. Hughes, “Prostaglandin H synthase and xenobiotic oxidation,” Annual Review of Pharmacology and Toxicology, vol. 30, no. 1, pp. 1-45, 1990.
11. A. P. Kulkarni, “Lipoxygenase - a versatile biocatalyst for biotransformation of endobiotics and xenobiotics,” Cellular and Molecular Life Sciences, vol. 58, no. 12, pp. 1805-1825, 2001.
12. L. A. Pham-Huy, H. He, and C. Pham-Huy, “Free radicals, antioxidants in disease and health,” International journal of biomedical science: IJBS, vol. 4, no. 2, pp. 89-96, 2008.
13. A. Devarajan, D. Shih, and S. T. Reddy, “Inflammation, infection, cancer and all that the role of paraoxonases,” in Oxidative Stress and Inflammation in Non-communicable Diseases - Molecular Mechanisms and Perspectives in Therapeutics, J. Camps, Ed., vol. 824 of Advances in Experimental Medicine and Biology, pp. 33-41, Springer, Cham, 2014.
14. J. N. Moloney and T. G. Cotter, “ROS signalling in the biology of cancer,” Seminars in Cell & Developmental Biology, vol. 80, pp. 50-64, 2018.
15. M. Benhar, D. Engelberg, and A. Levitzki, “ROS, stress-activated kinases and stress signaling in cancer,” EMBO Reports, vol. 3, no. 5, pp. 420-425, 2002.
16. M. Valko, C. J. Rhodes, J. Moncol, M. Izakovic, and M. Mazur, “Free radicals, metals and antioxidants in oxidative stress-induced cancer,” Chemico-Biological Interactions, vol. 160, no. 1, pp. 1-40, 2006.
17. Y. Miyata, T. Matsuo, Y. Sagara, K. Ohba, K. Ohyama, and H. Sakai, “A mini-review of reactive oxygen species in urological cancer: correlation with NADPH oxidases, angiogenesis, and apoptosis,” International Journal of Molecular Sciences, vol. 18, no. 10, article 2214, 2017.
18. K. J. Cho, J. M. Seo, and J. H. Kim, “Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species,” Molecules and Cells, vol. 32, no. 1, pp. 1-5, 2011.
19. Á. Donkó, Z. Péterfi, A. Sum, T. Leto, and M. Geiszt, “Dual oxidases,” Philosophical Transactions of the Royal Society B: Biological Sciences, vol. 360, no. 1464, pp. 2301-2308, 2005.
20. G. Ferretti and T. Bacchetti, “Peroxidation of lipoproteins in multiple sclerosis,” Journal of the Neurological Sciences, vol. 311, no. 1-2, pp. 92-97, 2011.
21. A. Agarwal, A. Banerjee, and U. C. Banerjee, “Xanthine oxido-reductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling,” Critical Reviews in Biotechnology, vol. 31, no. 3, pp. 264-280, 2011.
22. K.-F. Rex Sheu and J. P. Blass, “The alpha-ketoglutarate dehydrogenase complex,” Annals of the New York Academy of Sciences, vol. 893, pp. 61-78, 1999.
23. J. Fang, T. Sawa, T. Akaike, and H. Maeda, “Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide,” Cancer Research, vol. 62, no. 11, pp. 3138-3143, 2002.
24. A. Ambrus, B. Torocsik, L. Tretter, O. Ozohanics, and V. Adam-Vizi, “Stimulation of reactive oxygen species generation by disease-causing mutations of lipoamide dehydrogenase,” Human Molecular Genetics, vol. 20, no. 15, pp. 2984-2995, 2011.
25. M. Lechner, P. Lirk, and J. Rieder, “Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin,” Seminars in Cancer Biology, vol. 15, no. 4, pp. 277-289, 2005.
26. R. L. Levine and E. R. Stadtman, “Oxidative modification of proteins during aging,” Experimental Gerontology, vol. 36, no. 9, pp. 1495-1502, 2001.
27. E. Niki, “Lipid peroxidation: physiological levels and dual biological effects,” Free Radical Biology and Medicine, vol. 47, no. 5, pp. 469-484, 2009.
28. H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81-128, 1991.
29. T. Senghore, Y. F. Li, F. C. Sung et al., “Biomarkers of oxidative stress associated with the risk of potentially malignant oral disorders,” Anticancer Research, vol. 38, no. 9, pp. 5211-5216, 2018.
30. K. Shimada, T. Fujii, S. Anai, K. Fujimoto, and N. Konishi, “ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder,” BMC Urology, vol. 11, no. 1, p. 22, 2011.
31. E. O. Sandes, C. Lodillinsky, Y. Langle et al., “Inducible nitric oxide synthase and PPARγ are involved in bladder cancer progression,” Journal of Urology, vol. 188, no. 3, pp. 967-973, 2012.
32. S. Kiliç, N. Bayraktar, A. Beytur, H. Ergin, M. Bayraktar, and M. Egri, “Can the levels of nitric oxide in the urine, serum and tumor tissue be putative markers for bladder cancer?,” International Journal of Urology, vol. 13, no. 8, pp. 1079-1085, 2006.
33. I. Gecit, M. Aslan, M. Gunes et al., “Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 5, pp. 739-743, 2012.
34. A. M. Eijan, L. E. Davel, H. A. Rueda, G. Rozenberg, E. S. De Lustig, and M. A. Jasnis, “Differential nitric oxide release and sensitivity to injury in different murine mammary tumor cell lines,” International Journal of Molecular Medicine, vol. 2, no. 5, pp. 625-630, 1998.
35. S. H. Jeon, J.-H. Park, and S.-G. Chang, “Expression of antioxidant enzymes (catalase, superoxide dismutase, and glutathione peroxidase) in human bladder cancer,” Korean Journal of Urology, vol. 48, no. 9, pp. 921-926, 2007.
36. N. Bayraktar, S. Kilic, M. R. Bayraktar, and N. Aksoy, “Lipid peroxidation and antioxidant enzyme activities in cancerous bladder tissue and their relation with bacterial infection: a controlled clinical study,” Journal of Clinical Laboratory Analysis, vol. 24, no. 1, pp. 25-30, 2010.
37. I. Gecit, R. Eryilmaz, S. Kavak et al., “The prolidase activity, oxidative stress, and nitric oxide levels of bladder tissues with or without tumor in patients with bladder cancer,” The Journal of Membrane Biology, vol. 250, no. 5, pp. 455-459, 2017.
38. I. Durak, H. Perk, M. Kavutçu, O. Canbolat, Ö. Akyol, and Y.§. Bedük, “Adenosine deaminase, 5′nucleotidase, xanthine oxidase, superoxide dismutase, and catalase activities in cancerous and noncancerous human bladder tissues,” Free Radical Biology and Medicine, vol. 16, no. 6, pp. 825-831, 1994.
39. S. Rouf Moustafa, “Association of superoxide dismutase, glutathione peroxidase, catalse, and xanthine oxidase with incidence of bladder cancer,” Cancer Research Journal, vol. 3, no. 2, pp. 17-27, 2015.
40. N. Badjatia, A. Satyam, P. Singh, A. Seth, and A. Sharma, “Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma,” Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 4, pp. 360-367, 2010.
41. C. R. Corso and A. Acco, “Glutathione system in animal model of solid tumors: from regulation to therapeutic target,” Critical Reviews in Oncology/Hematology, vol. 128, pp. 43-57, 2018.
42. C.-R. Yang, Y.-C. Ou, J.-H. Kuo et al., “Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response,” Cancer Letters, vol. 119, no. 2, pp. 157-162, 1997.
43. O. Yalçin, F. Karataş, F. A. Erulaş, and E. Özdemir, “The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder,” BJU International, vol. 93, no. 6, pp. 863-866, 2004.
44. I. Witte, S. Altenhofer, P. Wilgenbus et al., “Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells,” Cell Death & Disease, vol. 2, no. 1, article e112, 2011.
45. I. Witte, U. Foerstermann, A. Devarajan, S. T. Reddy, and S. Horke, “Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer,” Journal of Lipids, vol. 2012, Article ID 342806, 12 pages, 2012.
46. T. Bacchetti, G. Ferretti, and A. Sahebkar, “The role of paraoxonase in cancer,” Seminars in Cancer Biology, 2017.
47. M. M. Utanğaç, E. Yeni, M. Savaş et al., “Paraoxonase and arylesterase activity in bladder cancer,” Türk Üroloji Dergisi/Turkish Journal of Urology, vol. 43, no. 2, pp. 147-151, 2017.
48. S. Iftimie, A. García-Heredia, F. Pujol-Bosch et al., “Serum paraoxonase-1 concentration as a potential predictor of urinary bladder cancer recurrence. A five year follow-up study,” Archives of Medical Research, vol. 49, no. 2, pp. 119-122, 2018.
49. C. Kabaroglu, I. Mutaf, B. Boydak et al., “Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes,” Acta Cardiologica, vol. 59, no. 6, pp. 606-611, 2004.
50. O. Öztürk, Ö. F. Kağnici, T. Öztürk et al., “192R allele of para-oxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer,” Anticancer Research, vol. 29, no. 10, pp. 4041-4046, 2009.
51. T. Bacchetti, D. Sartini, V. Pozzi, T. Cacciamani, G. Ferretti, and M. Emanuelli, “Exploring the role of paraoxonase-2 in bladder cancer: analyses performed on tissue samples, urines and cell culturess,” Oncotarget, vol. 8, no. 17, pp. 28785-28795, 2017.
52. P. Whongsiri, C. Pimratana, U. Wijitsettakul et al., “LINE-1 ORF1 protein is up-regulated by reactive oxygen species and associated with bladder urothelial carcinoma progression,” Cancer Genomics & Proteomics, vol. 15, no. 2, pp. 143-151, 2018.
53. K. Uchida, M. Kanematsu, Y. Morimitsu, T. Osawa, N. Noguchi, and E. Niki, “Acrolein is a product of lipid peroxidation reaction: Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins,” Journal of Biological Chemistry, vol. 273, no. 26, pp. 16058-16066, 1998.
54. H. W. Lee, H. T. Wang, M. W. Weng et al., “Acrolein-and 4-aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells,” Oncotarget, vol. 5, no. 11, pp. 3526-3540, 2014.
55. İ. A. Yılma, T. Akçay, U. Çakatay, A. Telci, S. Ataus, and V. Yalçın, “Relation between bladder cancer and protein oxidation,” International Urology and Nephrology, vol. 35, no. 3, pp. 345-350, 2003.
56. T. B. Kryston, A. B. Georgiev, P. Pissis, and A. G. Georgakilas, “Role of oxidative stress and DNA damage in human carcinogenesis,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 711, no. 1-2, pp. 193-201, 2011.
57. C. Cao, T. Lai, M. Li et al., “Smoking-promoted oxidative DNA damage response is highly correlated to lung carcinogenesis,” Oncotarget, vol. 7, no. 14, pp. 18919-18926, 2016.
58. T. Wada, N. Tanji, A. Ozawa et al., “Mitochondrial DNA mutations and 8-hydroxy-2′-deoxyguanosine content in Japanese patients with urinary bladder and renal cancers,” Anticancer Research, vol. 26, no. 5A, pp. 3403-3408, 2006.
59. A. Cormio, F. Sanguedolce, C. Musicco et al., “Mitochondrial dysfunctions in bladder cancer: exploring their role as disease markers and potential therapeutic targets,” Critical Reviews in Oncology/Hematology, vol. 117, pp. 67-72, 2017.
60. K. M. Patel, K. E. van der Vos, C. G. Smith et al., “Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer,” Scientific Reports, vol. 7, no. 1, article 5554, 2017.